Head-to-head evidence
MB12 vs Sasanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
MB12
Developed by Laboratorio Elea Phoenix S.A.
NCT05668650 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.
Sasanlimab
Developed by Pfizer
NCT04181788 · Phase 1/2 · completed
Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.
Next expected readout: October 2026 · NCT06447662 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MB12's landscape · Sasanlimab's landscape